表紙
市場調査レポート

パーキンソン病;世界の薬剤予測と将来の市場分析

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

発行 GlobalData 商品コード 305464
出版日 ページ情報 英文 318 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
パーキンソン病;世界の薬剤予測と将来の市場分析 PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
出版日: 2015年06月01日 ページ情報: 英文 318 Pages
概要

パーキンソン病は進行性の疾患で、動作緩慢、筋硬直、震え、姿勢の不安定などと特徴づけられます。2番目に多い神経変性疾患として、特に高齢者に広がっています。今後患者数は欧米主要国および日本・ブラジルにおいて2012年の320万人から2022年には430万に増加すると予測されています。

当レポートでは、パーキンソン病の概要と市場収益、将来予測、市場の特性とアンメットニーズ、パイプライン動向、市場の現状と将来的競合動向、および参入企業のプロファイルなどをまとめています。

第1章 目次

第2章 イントロダクション

第3章 疾患概要

  • 病因と病態生理学
    • 病因
    • 病態生理学
    • 予後
    • クオリティオブライフ
  • 症状

第4章 疫学

  • 疾患の背景
  • リスクファクターと共存症
  • 世界の動向
    • 米国
    • EU5か国
    • 日本
    • ブラジル
  • 予測方法
  • パーキンソン病の疫学的予測
  • 考察

第5章 疾患の管理

  • 概要
    • 診断:英国ブレインバンク基準
    • 治療ガイドラインと主な処方薬
  • 治療概要
    • ドーパミン作用による治療
    • 病期別治療法
    • その他の治療法
  • パーキンソン病の評価基準
  • 国別診断と治療

第6章 競合評価

  • 概要
  • 戦略的競合評価
  • 製品プロファイル:Levodopa併用療法
  • 製品プロファイル:COMT阻害剤
  • ドーパミン作動薬
  • 製品プロファイル:MAO-B阻害剤
  • 製品プロファイル:アデノシン2A阻害剤
  • 製品プロファイル:その他

第7章 機会とアンメットニーズ

  • 概要
  • 運動の合併症治療
  • 非運動型症状と認知症
  • 神経保護/疾患修飾剤
  • 製剤の改良
  • 信頼性の高いバイオマーカーの同定
  • 治験デザインの改善

第8章 パイプライン評価

  • 概要
  • 治験マッピング
  • 臨床開発における有望薬剤

第9章 現在および将来の市場参入企業

  • 概要
  • 企業戦略動向
  • 企業プロファイル
    • Merck
    • Roche
    • AbbVie
    • UCB
    • GlaxoSmithKline
    • Novartis
    • Orion
    • Newron
    • Civitas
    • Impax
    • Lundbeck

第10章 市場見通し

  • 世界市場
    • 予測
    • 促進因子と障壁
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • ブラジル

第11章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC011EPIDR

Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. It is expected that the prevalence of Parkinson's disease in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Brazil will increase from 3.2m people in 2012 to 4.3m people in 2022, driven by an aging population in all markets. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Highlights

Key Questions Answered

  • According to KOLs, what are the most important unmet needs in PD? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2022?
  • With the recent launch of Xadago and Rytary and an additional four drugs in the late-stage pipeline, which products are forecast to generate the highest sales over 2012-2022?
  • What corporate strategies have been employed for recent product launches? What opportunities remain for new entrants?
  • An aging population is expected to increase prevalence of PD in all markets from 2012-2022. How will epidemiological changes impact the growth of the future PD market?
  • What governmental developments are likely to affect reimbursement and generic erosion of PD drugs? What type of impact will this have on the markets covered over the forecast period?

Key Findings

  • Population increases, especially in the elderly, will be a key driving force in the global PD market.
  • With several small biotech and pharmaceutical companies involved in mid-stage development of PD products, there will be ample opportunity for partnerships with Big Pharma.
  • Levodopa based therapy will remain the gold standard of care with advancements in administration, including the introduction of slow-release formulations and an emergency use inhaler.
  • Several unmet needs are expected to remain after the forecast period, as advancements in the control of non-motor symptoms and in the development of disease-modifying therapies are lagging.

Scope

  • Overview of Parkinson's disease, including etiology, pathophysiology, motor and non-motor symptoms, and quality of life.
  • Annualized Parkinson's disease market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PD market.
  • Pipeline analysis: comprehensive data split across different Phases and emerging trends, specifically Biotie's tozadenant, Acorda's CVT-301, Bial's opicapone, and Intec's CD/LD-GR, and well as the recently launched drugs: Newron/Zambon's Xadago and Impax's Rytary (IPX066).
  • Analysis of the current and future market competition in the global Parkinson's disease market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the PD market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PD market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global PD market from 2012-2022.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
    • 4.2.1. The risk of developing Parkinson's disease progressively increases with age
    • 4.2.2. The risk for Parkinson's disease is increased with Parkinson's disease-causing mutations
    • 4.2.3. Men are 1.5 times more likely to develop Parkinson's disease than women, though the difference may be the result of varying exposures to environmental factors
    • 4.2.4. Chemicals, along with exposure to other environmental factors, increase the risk of developing Parkinson's disease
    • 4.2.5. 38% of Parkinson's disease cases experienced depression and/or anxiety compared with only 8% of controls
  • 4.3. Global and Historical Trends
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Japan
    • 4.3.4. Brazil
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast of Parkinson's Disease (2012-2022)
    • 4.5.1. Prevalent Cases of Parkinson's Disease
    • 4.5.2. Age-Specific Prevalent Cases of Parkinson's Disease
    • 4.5.3. Sex-Specific Prevalent Cases of Parkinson's Disease
    • 4.5.4. Age-Standardized Prevalence of Parkinson's Disease
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Overview
    • 5.1.1. Diagnosis - The UK Brain Bank Criteria
    • 5.1.2. Treatment Guidelines and Leading Prescribed Drugs
  • 5.2. Treatment Synopsis
    • 5.2.1. Dopaminergic Therapy Classes
    • 5.2.2. Treatment of Parkinson's Disease by Stage
    • 5.2.3. Other Treatment Options
  • 5.3. Parkinson's Disease Assessment Scales
    • 5.3.1. Unified Parkinson's Disease Rating Scale (UPDRS)
    • 5.3.2. Hoehn and Yahr Clinical Staging
    • 5.3.3. Other Clinical Assessments
  • 5.4. Diagnosis and Treatment of Parkinson's Disease by Country
    • 5.4.1. US
    • 5.4.2. France
    • 5.4.3. Germany
    • 5.4.4. Italy
    • 5.4.5. Spain
    • 5.4.6. UK
    • 5.4.7. Japan
    • 5.4.8. Brazil

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Strategic Competitor Assessment
  • 6.3. Product Profiles - Levodopa Combination Therapy
    • 6.3.1. Madopar (levodopa/benserazide)
    • 6.3.2. Sinemet (carbidopa/levodopa)
    • 6.3.3. Rytary
    • 6.3.4. Duodopa (carbidopa/levodopa intestinal gel)
  • 6.4. Product Profiles - COMT Inhibitors
    • 6.4.1. Stalevo/Comtan (entacapone)
  • 6.5. Dopamine Agonists
    • 6.5.1. Neupro (rotigotine transdermal patch)
    • 6.5.2. Requip/Requip XL (ropinirole)
    • 6.5.3. Apokyn (apomorphine)
  • 6.6. Product Profiles - MAO-B Inhibitors
    • 6.6.1. Azilect (rasagiline)
    • 6.6.2. Xadago (safinamide)
  • 6.7. Product Profiles - Adenosine 2A Inhibitor
    • 6.7.1. Nouriast (istradefylline)
  • 6.8. Product Profiles - Other Therapies

7. Opportunity and Unmet Need

  • 7.1. Overview
  • 7.2. Treatment of Motor Complications - Dyskinesias and OFF Episodes
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Treatment of Non-Motor Symptoms and Dementia
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Neuroprotective/Disease-Modifying Agents
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Improved Drug Formulations
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Identification of Reliable Biomarkers
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity
  • 7.7. Improved Clinical Trial Design
    • 7.7.1. Unmet Need
    • 7.7.2. Gap Analysis
    • 7.7.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Class/Patient Population/Biomarkers/Line of Therapy
  • 8.3. Promising Drugs in Clinical Development
    • 8.3.1. Tozadenant
    • 8.3.2. CVT-301
    • 8.3.3. Opicapone
    • 8.3.4. AP - CD/LD
    • 8.3.5. Other Late-Stage Pipeline Products

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Merck
    • 9.3.2. Roche
    • 9.3.3. AbbVie
    • 9.3.4. UCB
    • 9.3.5. GlaxoSmithKline
    • 9.3.6. Novartis
    • 9.3.7. Orion
    • 9.3.8. Newron
    • 9.3.9. Impax
    • 9.3.10. Lundbeck

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. UK
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers
  • 10.9. Brazil
    • 10.9.1. Forecast
    • 10.9.2. Key Events
    • 10.9.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed Parkinson's Disease Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Compliance Assumptions
    • 11.4.7. Individual Drug Assumptions
    • 11.4.8. Generic Erosion
    • 11.4.9. Pricing of Pipeline Agents
  • 11.5. Physicians and Specialists Included in this Study
  • 11.6. About the Authors
    • 11.6.1. Author
    • 11.6.2. Epidemiologist
    • 11.6.3. Global Head of Healthcare
  • 11.7. About GlobalData
  • 11.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Parkinson's Disease
  • Table 2: Risk Factors and Comorbidities for Parkinson's Disease
  • Table 3: Sources of Diagnosed Prevalence Data Used in the Epidemiology Forecast
  • Table 4: 8MM, Diagnosed Prevalent Cases of Parkinson's Disease, Ages ≥65 Years, Both Sexes, N, Select Years, 2012-2022
  • Table 5: 8MM, Diagnosed Prevalent Cases of Parkinson's Disease, by Age, N (Row %), 2012
  • Table 6: 8MM, Diagnosed Prevalent Cases of Parkinson's Disease, by Sex, N (Row %), 2012
  • Table 7: UK Brain Bank Diagnostic Criteria
  • Table 8: Diagnosis and Treatment Guidelines for Parkinson's Disease
  • Table 9: Most Prescribed Drugs for Parkinson's Disease by Class in the Global Markets, 2014
  • Table 10: Dopaminergic Therapy in Parkinson's Disease
  • Table 11: UPDRS Clinical Assessment of Disease Severity
  • Table 12: Parkinson's Disease Assessment Scales Used in Clinical Trials
  • Table 13: Parkinson's Disease, Country Profile - US
  • Table 14: Parkinson's Disease, Country Profile - France
  • Table 15: Parkinson's Disease, Country Profile - Germany
  • Table 16: Parkinson's Disease, Country Profile - Italy
  • Table 17: Parkinson's Disease, Country Profile - Spain
  • Table 18: Parkinson's Disease, Country Profile - UK
  • Table 19: Parkinson's Disease, Country Profile - Japan
  • Table 20: Parkinson's Disease, Country Profile - Brazil
  • Table 21: Treatment of Motor Symptoms in Parkinson's Disease
  • Table 22: Leading Treatments for Parkinson's Disease, 2014
  • Table 23: Product Profile - Madopar
  • Table 24: Madopar SWOT Analysis, 2014
  • Table 25: Global Sales Forecasts ($m) for Madopar, 2012-2022
  • Table 26: Global Sales Forecasts ($m) for Madopar CR, 2012-2022
  • Table 27: Product Profile - Sinemet
  • Table 28: Sinemet SWOT Analysis, 2014
  • Table 29: Global Sales Forecasts ($m) for Sinemet, 2012-2022
  • Table 30: Global Sales Forecasts ($m) for Sinemet CR, 2012-2022
  • Table 31: Product Profile - Rytary
  • Table 32: Rytary SWOT Analysis, 2014
  • Table 33: Global Sales Forecasts ($m) for Rytary, 2012-2022
  • Table 34: Product Profile - Duodopa
  • Table 35: Duodopa SWOT Analysis, 2014
  • Table 36: Global Sales Forecasts ($m) for Duodopa, 2012-2022
  • Table 37: Product Profile - Stalevo
  • Table 38: Product Profile - Comtan
  • Table 39: Stalevo/Comtan SWOT Analysis, 2014
  • Table 40: Global Sales Forecasts ($m) for Stalevo/Comtan, 2012-2022
  • Table 41: Product Profile - Neupro
  • Table 42: Neupro SWOT Analysis, 2014
  • Table 43: Global Sales Forecasts ($m) for Neupro, 2012-2022
  • Table 44: Product Profile - Requip/Requip XL
  • Table 45: Requip/Requip XL SWOT Analysis, 2014
  • Table 46: Global Sales Forecasts ($m) for Requip/Requip XL, 2012-2022
  • Table 47: Product Profile - Apokyn
  • Table 48: Apokyn SWOT Analysis, 2014
  • Table 49: Global Sales Forecasts ($m) for Apokyn Continuous Infusion, 2012-2022
  • Table 50: Global Sales Forecasts ($m) for Apokyn Pen, 2012-2022
  • Table 51: Product Profile - Azilect
  • Table 52: Azilect SWOT Analysis, 2014
  • Table 53: Global Sales Forecasts ($m) for Azilect, 2012-2022
  • Table 54: Product Profile - Xadago
  • Table 55: Summary of Relevant Clinical Trials for Xadago
  • Table 56: Xadago SWOT Analysis, 2014
  • Table 57: Global Sales Forecasts ($m) for Xadago, 2012-2022
  • Table 58: Product Profile - Nouriast
  • Table 59: Nouriast SWOT Analysis, 2014
  • Table 60: Global Sales Forecasts ($m) for Nouriast, 2012-2022
  • Table 61: Summary of Alternative Parkinson's Disease Therapies
  • Table 62: Unmet Need and Opportunity in Parkinson's Disease
  • Table 63: Dyskinesia Pipeline, 2014
  • Table 64: Dementia Pipeline, 2014
  • Table 65: Parkinson's Disease-Modifying Therapeutics Pipeline, 2014
  • Table 66: Product Profile - Tozadenant
  • Table 67: Tozadenant SWOT Analysis, 2014
  • Table 68: Global Sales Forecasts ($m) for Tozadenant, 2012-2022
  • Table 69: Product Profile - CVT-301
  • Table 70: CVT-301 SWOT Analysis, 2014
  • Table 71: Global Sales Forecasts ($m) for CVT-301, 2012-2022
  • Table 72: Product Profile - Opicapone
  • Table 73: Opicapone SWOT Analysis, 2014
  • Table 74: Global Sales Forecasts ($m) for Opicapone, 2012-2022
  • Table 75: Product Profile - AP - CD/LD
  • Table 76: Summary of Relevant Clinical Trials for AP - CD/LD
  • Table 77: AP - CD/LD SWOT Analysis, 2014
  • Table 78: Late-Stage Pipeline, 2015
  • Table 79: Key Companies in the Parkinson's Market, 2015
  • Table 80: Merck's Parkinson's Disease Portfolio Assessment, 2014
  • Table 81: Merck's PD SWOT Analysis, 2014
  • Table 82: Roche's Parkinson's Disease Portfolio Assessment, 2014
  • Table 83: Roche's PD SWOT Analysis, 2014
  • Table 84: AbbVie's Parkinson's Disease Portfolio Assessment, 2014
  • Table 85: AbbVie's PD SWOT Analysis, 2014
  • Table 86: UCB's Parkinson's Disease Portfolio Assessment, 2014
  • Table 87: UCB's PD SWOT Analysis, 2014
  • Table 88: GSK's Parkinson's Disease Portfolio Assessment, 2014
  • Table 89: GSK's PD SWOT Analysis, 2014
  • Table 90: Novartis' Parkinson's Disease Portfolio Assessment, 2014
  • Table 91: Novartis' PD SWOT Analysis, 2014
  • Table 92: Orion's Parkinson's Disease Portfolio Assessment, 2014
  • Table 93: Orion's PD SWOT Analysis, 2014
  • Table 94: Newron's Parkinson's Disease Portfolio Assessment, 2014
  • Table 95: Newron's PD SWOT Analysis, 2014
  • Table 96: Impax's Parkinson's Disease Portfolio Assessment, 2014
  • Table 97: Impax's PD SWOT Analysis, 2014
  • Table 98: Lundbeck's Disease/Therapy Portfolio Assessment, 2014
  • Table 99: Lundbeck's SWOT Analysis, 2014
  • Table 100: Global Sales Forecasts ($m) for Parkinson's Disease, 2012-2022
  • Table 101: Parkinson's Disease Market - Drivers and Barriers, 2012-2022
  • Table 102: Sales Forecasts ($m) for Parkinson's Disease in the US, 2012-2022
  • Table 103: Key Events Impacting Sales for Parkinson's Disease in the US, 2012-2022
  • Table 104: Parkinson's Disease Market in the US - Drivers and Barriers, 2012-2022
  • Table 105: Sales Forecasts ($m) for Parkinson's Disease in France, 2012-2022
  • Table 106: Key Events Impacting Sales for Parkinson's Disease in France, 2012-2022
  • Table 107: Parkinson's Disease Market in France - Drivers and Barriers, 2012-2022
  • Table 108: Sales Forecasts ($m) for Parkinson's Disease in Germany, 2012-2022
  • Table 109: Key Events Impacting Sales for Parkinson's Disease in Germany, 2012-2022
  • Table 110: Parkinson's Disease Market in Germany - Drivers and Barriers, 2012-2022
  • Table 111: Sales Forecasts ($) for Parkinson's Disease in Italy, 2012-2022
  • Table 112: Key Events Impacting Sales for Parkinson's Disease in Italy, 2012-2022
  • Table 113: Parkinson's Disease Market in Italy - Drivers and Barriers, 2012-2022
  • Table 114: Sales Forecasts ($m) for Parkinson's Disease in Spain, 2012-2022
  • Table 115: Key Events Impacting Sales for Parkinson's Disease in Spain, 2012-2022
  • Table 116: Parkinson's Disease Market in Spain - Drivers and Barriers, 2012-2022
  • Table 117: Sales Forecasts ($m) for Parkinson's Disease in the UK, 2012-2022
  • Table 118: Key Events Impacting Sales for Parkinson's Disease in the UK, 2012-2022
  • Table 119: Parkinson's Disease Market in the UK - Drivers and Barriers, 2012-2022
  • Table 120: Sales Forecasts ($m) for Parkinson's Disease in Japan, 2012-2022
  • Table 121: Key Events Impacting Sales for Parkinson's Disease in Japan, 2012-2022
  • Table 122: Parkinson's Disease Market in Japan - Drivers and Barriers, 2012-2022
  • Table 123: Sales Forecasts ($m) for Parkinson's Disease in Brazil, 2012-2022
  • Table 124: Key Events Impacting Sales for Parkinson's Disease in Brazil, 2012-2022
  • Table 125: Parkinson's Disease Market in Brazil - Drivers and Barriers, 2012-2022
  • Table 126: Key Launch Dates
  • Table 127: Key Patent Expiries

List of Figures

  • Figure 1: 8MM, Age-Adjusted Mortality Rate of Parkinson's Disease, Both Sexes, N, 2011
  • Figure 2: 8MM, Diagnosed Prevalent Cases of Parkinson's Disease, Ages ≥65 Years, Both Sexes, N, Select Years, 2012-2022
  • Figure 3: 8MM, Diagnosed Prevalent Cases of Parkinson's Disease, by Age, N, 2012
  • Figure 4: 8MM, Diagnosed Prevalent Cases of Parkinson's Disease, by Sex, N, 2012
  • Figure 5: 8MM, Age-Standardized Prevalence (%) of Parkinson's Disease, 2012
  • Figure 6: Overview - L-dopa Metabolism and Inhibitor Classes
  • Figure 7: Overview - Treatment of Motor Symptoms of Parkinson's Disease
  • Figure 8: Pharmacokinetics of Levodopa
  • Figure 9: Clinical Trials for Parkinson's Disease by Class and Therapeutic Strategy, 2014
  • Figure 10: Parkinson's Disease - Phase II-III Pipeline, Segmented by Indication, 2014
  • Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in Parkinson's Disease, 2012-2022
  • Figure 12: Company Portfolio Gap Analysis in Parkinson's Motor Symptoms, 2012-2022
  • Figure 13: Global Sales for Parkinson's Disease by Country, 2012-2022
  • Figure 14: Sales for Parkinson's Disease in the US by Drug Class, 2012-2022
  • Figure 15: Sales for Parkinson's Disease in France by Drug Class, 2012-2022
  • Figure 16: Sales for Parkinson's Disease in Germany by Drug Class, 2012-2022
  • Figure 17: Sales for Parkinson's Disease in Italy by Drug Class, 2012-2022
  • Figure 18: Sales for Parkinson's Disease in Spain by Drug Class, 2012-2022
  • Figure 19: Sales for Parkinson's Disease in the UK by Drug Class, 2012-2022
  • Figure 20: Sales for Parkinson's Disease in Japan by Drug Class, 2012-2022
  • Figure 21: Sales for Parkinson's Disease in Brazil by Drug Class, 2012-2022
Back to Top